OKYO PHARMA LTD SP.ADR/65 (OK10) - Total Liabilities
Based on the latest financial reports, OKYO PHARMA LTD SP.ADR/65 (OK10) has total liabilities worth €8.06 Million EUR (≈ $9.42 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OKYO PHARMA LTD SP.ADR/65 equity growth rate to track the company's year-over-year net asset growth rate.
OKYO PHARMA LTD SP.ADR/65 - Total Liabilities Trend (2022–2025)
This chart illustrates how OKYO PHARMA LTD SP.ADR/65's total liabilities have evolved over time, based on quarterly financial data.
OKYO PHARMA LTD SP.ADR/65 Competitors by Total Liabilities
The table below lists competitors of OKYO PHARMA LTD SP.ADR/65 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Berkeley Group Holdings plc
LSE:BKG
|
UK | GBX2.84 Billion |
|
PESTECH International Bhd
KLSE:5219
|
Malaysia | RM1.27 Billion |
|
CORESTATE Capital Holding S.A
F:CCAP
|
Germany | €725.00 Million |
|
UPA Corporation Bhd
KLSE:7757
|
Malaysia | RM34.80 Million |
|
Sumi Indo Kabel Tbk
JK:IKBI
|
Indonesia | Rp25.31 Million |
|
KCI Limited
KQ:036670
|
Korea | ₩18.97 Billion |
|
Halcyon Technology Public Company Limited
BK:HTECH
|
Thailand | ฿304.79 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down OKYO PHARMA LTD SP.ADR/65's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of OKYO PHARMA LTD SP.ADR/65.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OKYO PHARMA LTD SP.ADR/65's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OKYO PHARMA LTD SP.ADR/65 (2022–2025)
The table below shows the annual total liabilities of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €9.23 Million ≈ $10.79 Million |
+24.34% |
| 2024-03-31 | €7.42 Million ≈ $8.68 Million |
+2.26% |
| 2023-03-31 | €7.26 Million ≈ $8.48 Million |
+436.30% |
| 2022-03-31 | €1.35 Million ≈ $1.58 Million |
-- |
About OKYO PHARMA LTD SP.ADR/65
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptid… Read more